All In Biotech

Drug Trial Radar · NCT06117540

A Study of WX390 in Patients With Advanced Solid Tumors

An Open-label, Single-arm, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of WX390 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

70

Planned (sponsor's estimate)

Start

May 11, 2021

Primary completion

Jun 12, 2025

Study completion Jun 12, 2026

Sponsor

Sponsor type
Industry
First posted
Nov 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the efficacy and safety of WX390 in patients with advanced solid tumors. The main questions it aims to answer are: * PFS, OS, DoR at week 48; * antitumor effects at week 24 and week 48. Participants will be treated with WX390 orally, and follow the efficacy and safety evaluation according to the protocol.

Conditions

  • Solid Tumor

Interventions

  • WX390Drug

    WX390 tablet, 1.1 mg once a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Week 48
  2. Overall Survival (OS)Time frame: Week 48
  3. Duration of Response (DOR)Time frame: Week 48
  4. Progression-free survival rate (PFSR)Time frame: Week 24 and Week 48
  5. Objective Response Rate (ORR)Time frame: Week 24 and Week 48
  6. Disease control rate (DCR)Time frame: Week 24 and Week 48

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.